Passive Immunotherapy In Patients With SARS CoV-2 (CoV-PlasGal)

Fundacin Biomedica Galicia Sur

Status and phase

Completed

Phase 2

Conditions

COVID-19

Treatments

Biological: Convalescent plasma

Study type

Interventional

Funder types

Other

Identifiers

NCT05578391

CoV-PlasGal

Details and patient eligibility

About

Plasma from convalescent individuals (convalescent plasma, CP) has been used for more than a hundred years for the treatment of infectious diseases. Among patients with COVID-19, it has been used first, in patients with severe infection. Although it is a safe treatment, it has not been possible to demonstrate a reduction in mortality in cases of acute respiratory distress syndrome.

The objective of the clinical trial is to evaluate the efficacy and safety of the early use (less than 5 days of symptoms) of CP in patients infected with SARS-CoV-2 with risk factors for severe disease.

The primary efficacy endpoint was the proportion of patients requiring oxygen therapy to maintain saturation >93% on day 14. Secondary objectives included, evaluation of the safety of the treatment, measured as the appearance of some adverse event related to the CP infusion; the evolution of COVID-19 symptoms and WHO progression scale status at day 14 and 28 after inclusion; the need for hospitalization due to progression of COVID-19. COVID-19 progression was considered as worsening of respiratory symptoms requiring oxygen therapy at some point. Finally, death from any cause was evaluated at 28 days, after inclusion in the study.

Enrollment

61 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients with SARS-CoV-2 infection, confirmed by any validated microbiological technique, and with one or more symptoms associated with COVID-19 with ≤5 days of evolution and with an oxygen saturation ≥93% breathing room air.

In addition, the patients had to present some risk factor for severe disease:

Chronic heart failure (NYHA ≥ 2)
Arterial hypertension under pharmacological treatment
Chronic lung disease: COPD (bronchitis, emphysema or chronic obstruction) with dyspnoea at least on moderate exertion, or moderate-severe asthma (that required inhaled corticosteroids to control symptoms or had received systemic corticosteroids during the last year due to decompensation)
Chronic renal failure (glomerular filtration rate <60 ml/min/1.73 m², by CKD- ILD)
Diabetes mellitus requiring pharmacological treatment or obesity grade ≥ I (BMI ≥30 Kg/m2).
Patients ≥65 years were included, regardless of other risk factors.

Exclusion criteria

Duration of symptoms >5 days
Dyspnoea at rest
Need for supplemental oxygen to maintain O2 saturation >93%
Solid neoplastic or haematologic disease (except skin cancer) with active treatment in the last 3 months before the onset of symptoms
Patients under chronic corticosteroid treatment (equivalent to prednisone 10 mg/d for at least 28 days) or immunosuppressive treatment
Decompensated liver cirrhosis
Participation in another clinical trial
History of hypersensitivity to haematological derivatives
Pregnancy or lactation,
AST/ALT >5 times the upper limit of normal or at baseline in patients with chronic liver disease
Any condition that in the opinion of the investigator limits participation in the study.
Patients who had received monoclonal antibodies against SARS-CoV-2